SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
March 21, 2000
Date of Report (Date of earliest event reported)
WARNER-LAMBERT COMPANY
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-3608 22-1598912
(Commission File Number) (IRS Employer Identification No.)
201 Tabor Road, Morris Plains, New Jersey 07950-2693
(Address of principal executive offices) (Zip Code)
(973) 385-2000
(Registrant's telephone number, including area code)
Item 5. Other Events.
Attached hereto and incorporated herein by reference as Exhibit
99.1 is a copy of a press release issued by Warner-Lambert Company on March
21, 2000.
Item 7. Financial Statements and Exhibits
(c) Exhibits
(99.1) Press Release, dated March 21, 2000.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
WARNER-LAMBERT COMPANY
By: /s/ Rae G. Paltiel
---------------------------------
Name: Rae G. Paltiel
Title: Secretary
Dated: March 23, 2000
EXHIBIT INDEX
(99.1) Press Release, dated March 21, 2000.
Exhibit 99.1
MORRIS PLAINS, N.J., March 21, 2000 -- Warner-Lambert Company announced
today that it is voluntarily discontinuing the sale of REZULIN
(troglitazone) Tablets, its therapy for the treatment of type 2 diabetes,
although the Company continues to believe that the benefits of the drug
outweigh its associated risks.
Patients taking REZULIN should consult with their physicians as soon
as possible to discuss alternative therapies. Warner-Lambert will work
closely with the Food and Drug Administration and other constituencies to
assure a safe and efficient transition for patients as they switch to
alternative therapies.
The Company has always believed that it is essential for patients and
physicians to receive accurate and objective information regarding the
benefits and risks of REZULIN. It was for this reason that Warner-Lambert
requested a public meeting of the FDA's expert Advisory Committee. However,
repeated media reports sensationalizing the risks associated with REZULIN
therapy have created an environment in which patients and physicians are
simply unable to make well-informed decisions regarding the safety and
efficacy of REZULIN. Under these circumstances, and after discussions this
evening with the FDA, we have decided it is in the best interests of
patients to discontinue marketing REZULIN at this time.
